The Deal
Tuesday, November 24, 
3:40 am


Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
NOT A SUBSCRIBER?

Glaxo snares Stiefel Labs

Posted on April 20, 2009 6:30 PM
The U.K.'s GlaxoSmithKline plc announced plans Monday to buy Stiefel Laboratories Inc. for up to $3.6 billion in a deal that will almost triple the size of its dermatology unit.

GlaxoSmithKline, of London, agreed to pay $2.9 billion in cash for Stiefel and to assume $400 million of net debt. The company may pay an additional $300 million if certain performance targets are met.

This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools.

To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button.

Dig deeper, with Pipeline.

  • 801 in-depth reports of M&A deals in the Healthcare sector
  • 582 company pages related to Pharmaceuticals
  • 484 articles related to GlaxoSmithKline plc
  • 11 articles related to Stiefel Laboratories Inc.
  • 10 years of news and analysis archives from the voice of The Deal Economy


Most searched keywords
  • Deutsche Bank
  • Skadden Arps
  • Pinnacle Foods
  • Concho Resources
  • Agrium Inc.
  • Birds Eye
  • Cantor Fitzgerald
  • Credit Suisse
  • Windstream Corp.
  • Goldman Sachs

EXISTING USERS


Username


Password


Forget your password?





Missing a product?



Sales Contact
Michael Crosby
mcrosby@thedeal.com
212.313.9325
Media Contact
Martha Brown
mbrown@thedeal.com
212.313.9218
Signing in signifies that you agree to our terms and conditions. View our privacy policy.